Michael Samuel Neuberger, one of the most brilliant molecular immunologists of his generation, died on 26 October 2013, just short of his 60th birthday. At the time of his death he was probably most widely known for delineating the role of DNA deamination in immunity through his pioneering work that explained how cytosine deamination drives the somatic hypermutation and class-switch recombination of antibody-encoding genes. Following the identification of activation-induced cytidine deaminase (AID) by Honjo and Durandy as the protein essential for both of those processes, Michael produced a series of seminal papers during 2002 that laid bare the mechanism that had perplexed immunologists for 30 years. The now-textbook scheme describes how by deaminating deoxycytidine in the variable domains of rearranged immunoglobulinencoding genes, AID creates uracil residues and thus, on its own or through the action of uracil DNA glycosylase, triggers the mutagenic cascade that drives affinity maturation. This insightful model also provided an explanation for how AID induces class-switch recombination by focusing deamination on both strands in the switch repeat sequences, which leads to recombination-inducing double-strand breaks. Michael found it intellectually pleasing that the answer to the puzzle of antibody diversification had such an elegant and logical simplicity. His work spawned a new field studying programmed deamination both by AID and its relatives, the APOBEC proteins, that has had ramifications for processes as diverse as the restriction of viral replication and the generation of the highly clustered mutations ('kataegis') seen in some cancers, all areas in which he led and left his mark.
Michael's earlier work has arguably had an even broader and more practical impact. He was the first person to be able to ectopically express immunoglobulin-encoding genes in lymphocytes, work that resulted in the identification of the key enhancer elements that control expression of immunoglobulin light chains. This technology was also instrumental in the invention of CDR (complementaritydetermining region) grafting, in collaboration with Greg Winter, and later led to the generation of mice that produce wholly human transgene-encoded antibodies and the foundation of a now multibillion-dollar industry.
Michael was born 2 November 1953 into an academically gifted family. His father, Albert Neuberger, was a noted biochemist who founded the modern field of glycobiology and who, coincidentally, supervised Fred Sanger's Ph.D. In 1974, after graduating with a First class Honors degree in Natural Sciences from Trinity College, Cambridge, Michael joined Brian Hartley as he moved from the Laboratory of Molecular Biology to head the Department of Biochemistry at Imperial College in London. There he joined
